These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16040258)

  • 41. Recent examples of novel secondary metabolites.
    Brown AG
    Folia Microbiol (Praha); 1995; 40(1):31-42. PubMed ID: 8851465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic analysis of large screening sets in drug discovery.
    Blower PE; Cross KP; Fligner MA; Myatt GJ; Verducci JS; Yang C
    Curr Drug Discov Technol; 2004 Jan; 1(1):37-47. PubMed ID: 16472218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early drug safety evaluation: biomarkers, signatures, and fingerprints.
    Roberts R; Cain K; Coyle B; Freathy C; Leonard JF; Gautier JC
    Drug Metab Rev; 2003 Nov; 35(4):269-75. PubMed ID: 14705860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Image-based multivariate profiling of drug responses from single cells.
    Loo LH; Wu LF; Altschuler SJ
    Nat Methods; 2007 May; 4(5):445-53. PubMed ID: 17401369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Flexible Workflow for Automated Bioluminescent Kinase Selectivity Profiling.
    Worzella T; Butzler M; Hennek J; Hanson S; Simdon L; Goueli S; Cowan C; Zegzouti H
    SLAS Technol; 2017 Apr; 22(2):153-162. PubMed ID: 28095176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular platforms for HTS: three case studies.
    Johnston PA; Johnston PA
    Drug Discov Today; 2002 Mar; 7(6):353-63. PubMed ID: 11893544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro models for immunogenicity prediction of therapeutic proteins.
    Groell F; Jordan O; Borchard G
    Eur J Pharm Biopharm; 2018 Sep; 130():128-142. PubMed ID: 29894817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of dosing schedule in animal experiments on compound progression decisions.
    Chen C
    Drug Discov Today; 2019 Feb; 24(2):371-376. PubMed ID: 30448352
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantifying the probability of pharmacological success to inform compound progression decisions.
    Zhou X; Graff O; Chen C
    PLoS One; 2020; 15(10):e0240234. PubMed ID: 33045007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemical target and pathway toxicity mechanisms defined in primary human cell systems.
    Berg EL; Yang J; Melrose J; Nguyen D; Privat S; Rosler E; Kunkel EJ; Ekins S
    J Pharmacol Toxicol Methods; 2010; 61(1):3-15. PubMed ID: 19879948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery.
    L Berg E; Hsu YC; Lee JA
    Adv Drug Deliv Rev; 2014 Apr; 69-70():190-204. PubMed ID: 24524933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.
    Bergamini G; Bell K; Shimamura S; Werner T; Cansfield A; Müller K; Perrin J; Rau C; Ellard K; Hopf C; Doce C; Leggate D; Mangano R; Mathieson T; O'Mahony A; Plavec I; Rharbaoui F; Reinhard F; Savitski MM; Ramsden N; Hirsch E; Drewes G; Rausch O; Bantscheff M; Neubauer G
    Nat Chem Biol; 2012 Apr; 8(6):576-82. PubMed ID: 22544264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological complexity and drug discovery: a practical systems biology approach.
    Berg EL; Kunkel EJ; Hytopoulos E
    Syst Biol (Stevenage); 2005 Dec; 152(4):201-6. PubMed ID: 16986261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Comparison of In Vitro Points of Departure with Human Blood Levels for Per- and Polyfluoroalkyl Substances (PFAS).
    Judson RS; Smith D; DeVito M; Wambaugh JF; Wetmore BA; Paul Friedman K; Patlewicz G; Thomas RS; Sayre RR; Olker JH; Degitz S; Padilla S; Harrill JA; Shafer T; Carstens KE
    Toxics; 2024 Apr; 12(4):. PubMed ID: 38668494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards reproducible structure-based chemical categories for PFAS to inform and evaluate toxicity and toxicokinetic testing.
    Patlewicz G; Richard AM; Williams AJ; Judson RS; Thomas RS
    Comput Toxicol; 2022 Nov; 24():. PubMed ID: 36969381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.
    Akasaka D; Iguchi S; Kaneko R; Yoshiga Y; Kajiwara D; Nakachi Y; Noma N; Tanaka K; Shimizu A; Hosoi F
    PLoS One; 2023; 18(2):e0282117. PubMed ID: 36821545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chlorogenic Acid Relieves the Lupus Erythematosus-like Skin Lesions and Arthritis in MRL/lpr Mice.
    Wang R; Yang X; You S; Hao M; Li J; Chen X; Jin J
    Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells.
    Houck KA; Friedman KP; Feshuk M; Patlewicz G; Smeltz M; Clifton MS; Wetmore BA; Velichko S; Berenyi A; Berg EL
    ALTEX; 2023; 40(2):248–270. PubMed ID: 36129398
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.